[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605934":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":69,"centralContacts":74,"locations":79,"responsibleParty":93,"collaborators":95,"id":111,"slug":112,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":113,"sex":119,"minAge":42,"maxAge":120,"enrollmentInfo":121,"targetDuration":42,"studyType":124,"phases":125,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":81,"whyStopped":42,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},{"fullName":5,"class":6},"Children's Cancer Group, China","NETWORK",[8,15,20,27],{"label":9,"type":10,"description":11,"interventionNames":12},"Risk group 1","OTHER","Complete resection of stage I or II disease: 3 courses (A-B-A) and 3 intrathecal injections(Cytarabine\u002FMethotrexate\u002FDexamethasone, age adjusted);",[13,14],"Drug: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone","Drug: Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone",{"label":16,"type":10,"description":17,"interventionNames":18},"Risk group 2","Not or incompletely resected stage I\u002FII disease and LDH \\\u003C2ULN: 5 courses (A--B--A--B--A) and 8 intrathecal injections;",[13,19],"Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone",{"label":21,"type":10,"description":22,"interventionNames":23},"Risk group 3","Stage III with LDH \\\u003C 2 ULN, or Stage I,II with LDH in 2 to 4 ULN : Preface followed by 6 courses (P(Cyclophosphamide\u002FVincristine\u002FPrednisone)-AA-BB-AA-BB-AA-BB) and 13 intrathecal injections(16 intrathecal injections with CNS2-3)",[24,25,26],"Drug: Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone","Drug: Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone","Drug: Prednisone,Vincristine, Cyclophosphamide",{"label":28,"type":10,"description":29,"interventionNames":30},"Risk group 4","Stage III with LDH≥2ULN, or Stage IV, or B-AL: Preface followed by 6 dose of rituximab (375mg\u002Fm2) combined 6 courses of chemotherapy, together with 13 intrathecal injections((16 intrathecal injections with CNS2-3): P-(Rituximab-Rituximab)AA-(Rituximab-Rituximab)BB-(Rituximab)AA-(Rituximab)BB-AA-BB; stage IV or B-AL with LDH≥5ULN:P-(Rituximab-Rituximab)AA-(Rituximab-Rituximab)BB-(Rituximab)AA-(Rituximab)BB-AA-BB-AA-BB, together with 17 intrathecal injections((21 intrathecal injections with CNS2-3)",[24,25,26],[32,39,43,47,53,59,65],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DRUG","Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone","Cyclophosphamide 800mg\u002Fm2, D1, then 200mg\u002Fm2, D2\\~4;Vincristine 1.5mg\u002Fm2 (MAX 2mg), D1; Cytarabine 1g\u002Fm2\u002Fdose, (2 doses, 12-hour interval), D4; Doxorubincin 20mg\u002Fm2, D2,3; Prednisone 60mg\u002Fm2, D1\\~7;Intrathecal injection, D1;",[9],[38],"Protocol A",{"type":33,"name":19,"description":40,"armGroupLabels":41,"otherNames":42},"Ifosphamide 1.2g\u002Fm2, D1\\~5; Etoposide, 60mg\u002Fm2, D3\\~5; Methotrexate, 0.5g\u002Fm2, D1;Vincristine 1.5mg\u002Fm2 (MAX 2mg), D1; Prednisone 60mg\u002Fm2, D1\\~7;Intrathecal injection, D1;",[9],null,{"type":33,"name":34,"description":44,"armGroupLabels":45,"otherNames":46},"Cyclophosphamide 800mg\u002Fm2, D1, then 200mg\u002Fm2, D2\\~4;Vincristine 1.5mg\u002Fm2 (MAX 2mg), D1; Cytarabine 1g\u002Fm2\u002Fdose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg\u002Fm2, D2,3; Prednisone 60mg\u002Fm2, D1\\~7;Intrathecal injection, D1,8;",[16],[38],{"type":33,"name":48,"description":49,"armGroupLabels":50,"otherNames":51},"Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone","Ifosphamide 1.2g\u002Fm2, D1\\~5; Etoposide, 60mg\u002Fm2, D3\\~5; Methotrexate, 0.5g\u002Fm2, D1;Vincristine 1.5mg\u002Fm2 (MAX 2mg), D1; Prednisone 60mg\u002Fm2, D1\\~7;Intrathecal injection, D1",[16],[52],"Protocol B",{"type":33,"name":54,"description":55,"armGroupLabels":56,"otherNames":57},"Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone","Cyclophosphamide 800mg\u002Fm2, D1, then 200mg\u002Fm2, D2\\~4; Vindelsine 3mg\u002Fm2 (MAX 5mg), D1; Cytarabine 2g\u002Fm2\u002Fdose, (2 doses, 12-hour interval), D4; Doxorubincin 20mg\u002Fm2, D2,3; Prednisone 60mg\u002Fm2, D1\\~7;Intrathecal injection, D1,4(CNS2-3),8",[21,28],[58],"Protocol AA",{"type":33,"name":60,"description":61,"armGroupLabels":62,"otherNames":63},"Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone","Ifosphamide 1.2g\u002Fm2, D1\\~5; Etoposide, 100mg\u002Fm2, D3\\~5; Methotrexate, 5g\u002Fm2, D1;Vindelsine 3mg\u002Fm2 (MAX 5mg), D1; Prednisone 60mg\u002Fm2, D1\\~7;Intrathecal injection, D1,8",[21,28],[64],"Protocol BB",{"type":33,"name":66,"description":67,"armGroupLabels":68,"otherNames":42},"Prednisone,Vincristine, Cyclophosphamide","Prednisone 45mg\u002Fm2, D1\\~7; Vincristine 1.5mg\u002Fm2(MAX 2mg), D1; Cyclophosphamide 300mg\u002Fm2, D1; Intrathecal injection, D1",[21,28],[70],{"name":71,"affiliation":72,"role":73},"Yi-jin Gao","Shanghai Children's Medical Center","PRINCIPAL_INVESTIGATOR",[75],{"name":71,"role":76,"phone":77,"phoneExt":42,"email":78},"CONTACT","+82064 86-21-38626161","gaoyijin@scmc.com.cn",[80],{"facility":72,"status":81,"city":82,"state":83,"zip":84,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":92,"contacts":42},"RECRUITING","Shanghai","Shanghai Municipality","201315","China","CN",{"type":88,"coordinates":89},"Point",[90,91],121.45806,31.22222,{"lat":91,"lon":90},{"type":94,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR",[96,97,99,101,103,105,107,109],{"name":72,"class":10},{"name":98,"class":10},"Nanjing Children's Hospital",{"name":100,"class":10},"Children's Hospital of Soochow University",{"name":102,"class":10},"West China Second University Hospital",{"name":104,"class":10},"Qilu Hospital of Shandong University",{"name":106,"class":10},"Tianjin Medical University Cancer Institute and Hospital",{"name":108,"class":10},"Xiangya Hospital of Central South University",{"name":110,"class":10},"Wuhan TongJi Hospital","100605934","phase-2-chemotherapy-with-rituximab-for-aggressive-b-nhl-in-children-and-adolescents-100605934",false,"NCT07168980","Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents","Intensive Chemotherapy Combined With Early, Adequate, and Intensive Use of Rituximab for Aggressive B-NHL in Children and Adolescents","B-NHL","Inclusion Criteria:\n\n* Histology or cytologically confirmed mature B-cell NHL\u002FAL(Burkitt, DLBCL, PMLBL,or aggressive mature B-cell NHL non other specified or specifiable)\n* Able to comply with scheduled follow-up and with management of toxicity\n* Signed informed consent\n\nExclusion Criteria:\n\n* Follicular lymphoma, MALT and nodular marginal zone are not included into this therapeutic study\n* Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology.\n* Evidence of pregnancy or lactation period. Past or current anti-cancer treatment except corticosteroids during less than one week.\n\nExclusion Criteria related to Rituximab :\n\n* Tumor cell negative for CD20\n* Prior exposure to rituximab\n* Hepatitis B carrier status history of HBV or positive serology.","ALL","18 Years",{"count":122,"type":123},87,"ESTIMATED","INTERVENTIONAL",[126,127],"PHASE2","PHASE3","The purpose of this study is to test whether intensive chemotherapy combined with early, adequate, and intensive use of Rituximab for aggressive B-NHL in children and adolescents can improve the EFS and OS compared with the historical study CCCG-BNHL-2015.",[130],"Mature B-cell Non-Hodgkin Lymphoma",[132,133,134,135],"mature B-cell non-Hodgkin lymphoma","children","adolescent","rituximab","2026-06-03",{"date":138,"type":139},"2026-06-04","ACTUAL",{"date":141,"type":139},"2025-07-01",{"date":143,"type":123},"2030-06-30",{"name":5,"class":6},1]